GRAL
GRAIL, Inc.
$61.64
-2.03%
2026-05-08
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Key Fundamentals
Forward P/E
-7.09
EPS (TTM)
$-10.30
ROE
-16.1%
Revenue Growth (YoY)
28.1%
Profit Margin
-253.2%
Debt/Equity
2.04
Price/Book
0.97
Market Cap
$2.66B
Avg Volume (10D)
632K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$109.04
60D Low
$41.50
Avg Volume
1.2M
Latest Close
$61.64
Get breakout alerts for GRAL
Sign up for Breakout Scanner to receive daily notifications when GRAL triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
GRAIL, Inc. (GRAL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GRAL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GRAL operates in the Healthcare sector within the Diagnostics & Research industry. Data is provided for informational purposes only and does not constitute financial advice.